Helen C. O’Neill has explored how the global reaction to the birth of genome-edited twins in 2018 echoed the condemnation surrounding the first successful use of in-vitro fertilisation (IVF) in 1978. Now regarded as a huge clinical success which has benefitted an estimated 16 million parents, at the time the development not only sparked moral outrage but led to political and legislative constraints.
Altering the genome, typically to better understand gene and protein function. This also paves the way for gene therapy.
Bioengineers based in the US have designed a “DNA-binding editorial assistant” that will allow gene-editing technology, like CRISPR, to access previously inaccessible genes of interest. The new protein design can be used to open up areas of the DNA that are obscured by chromatin, which would improve CRISPR efficiency and aid in developing more precise gene-editing techniques to combat disease.
Researchers at the Roslin Institute who cloned Dolly the sheep in 1996 are looking to create gene-edited squirrels for eventual release into the wild. This decision comes as an aim to save UK native red squirrels from North American native grey squirrels, which have seen a decrease in number since the grey’s arrival.
Earlier this week, He Jiankui, the scientist behind the world’s first gene-edited twin babies, was sentenced to three years in prison and fined three million yuan (£327,000) for “illegal medical practice”. In late 2018, He Jiankui along with his team carried out CRISPR gene editing on twin girls, dubbed Lulu and Nana, to provide immunity against HIV.
In late 2018, the world was shocked by the news of the birth of the first CRISPR gene edited twin babies. Chinese biophysicist He Jiankui carried out an experiment to create babies with a natural resistance to HIV by editing the CCR5 gene, known to play a role in the immune response.
The first gene editing clinical trial sponsored by US companies has released data to STAT news showing promising results using a CRISPR based therapy. Sickle cell anaemia and beta thalassemia patients required no further treatments after one appointment.
One year on from the birth of world’s first CRISPR-edited babies in China, Jennifer Doudna, writes in Science what this and the ensuing controversy has meant for the field and society’s perception of the technology, as well as to outline what should be done next.
In an exciting new development, researchers have now developed a CRISPR-Cas9 system complexed with Chemical Epigenetic Modifiers (CEMs) that allowed dose-dependent activation of gene expression.
A new version of the CRISPR-Cas9 protein has been developed that can increase the targeting efficiency of the gene editing process. Currently the CRISPR Cas-9 system is the most widely used gene editing technique. However, concerns about CRISPR editing genes other than the ones it is targeted to have hindered its introduction into gene-therapy treatments […]
Press Release from National Institute of Health The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease (SCD) and HIV. The Bill & Melinda Gates Foundation will also invest $100 million toward this goal. The […]
A new gene editing tool known as Prime Editing has been developed that could reverse the harmful mutations in over 89% of genetic diseases. Building on the CRISPR Success Currently the CRISPR Cas-9 system is the most widely used gene editing technique. However, concerns about CRISPR editing genes, other than the ones it is targeted […]
CRISPR gives us the ability to precisely edit genes within cells, and the technique holds enormous potential for transforming the gene therapy space. However, concerns about CRISPR editing genes other than the ones it is targeted to have hindered its introduction into patient treatments. Known as off-target mutations, these unintended gene edits caused by CRISPR […]
Manassas, VA – October 1, 2019 – ATCC launched its new ATCC Genome Portal, a publicly available database of reference-quality genome sequences matched to authenticated ATCC biological materials that will help researchers interpret and reproduce their results with confidence. The portal, which launched with an initial 250 genome sequences of widely used bacterial strains, delivers […]
Our guest contributor Dr Neil Lamb continues his fortnighty Shareable Science Blog with an extract from the annual guidebook ‘A Year in Genetics as Told by Tomorrow’s Textbooks‘. Neil is the Vice President for Educational Outreach at the HudsonAlpha Institute for Biotechnology and Shareable Science will explore how genetics is relevant to people in their […]
Molecular Assemblies recently announced a $12.2M series A financing to advance their enzymatic DNA synthesis technology. We talked to Michael Kamdar, the CEO and president of Molecular Assemblies, to discuss how enzymatic DNA synthesis could revolutionise biotechnology. FLG: Can you introduce Molecular Assemblies? MK: Molecular Assemblies is a synthetic biology company founded in 2013, and […]